

Attorney Docket No.: 5368.220-US

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## FILING UNDER 37 C.F.R. 1.53(b)

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



Sir:

This is a request for filing a patent application under 37 CFR 1.53(b).

INVENTOR(S)		
First Name	Middle Name	Family Name or Surname
1.Torben	1.Vedel	1.Borchert
2.Allan	2.	2.Svendsen
3.Carsten	3.	3.Andersen
4.Bjarne	4.	4.Nielsen
5.Torben	5.Lausgaard	5.Nissen
6.Soren	6.	6.Kjaerulff
	TITLE OF THE INVENT	ION
Alpha-Amylase Mutants		

The following application parts are enclosed:

[x] specification

72 pages

[x] Sequence Listing 26 pages

[x] Abstract

1 page

[x] Formal Drawings 7 pages

The filing fee is calculated as follows:

Basic Fee:

\$750.00

Total Claims:  $8 - 20 = 0 \times 18 =$ 

\$0.00

Independent Claims: 1 - 3 = 0 x 84 =

\$0.00

Total Fee:

\$750.00

Priority of Danish application nos. 1240/97 filed October 30, 1997, and PA 1998 00936, filed July 14, 1998 is claimed under 35 U.S.C. 119(a)-(d). A certified copy was filed in application no. 09/769,864, filed on January 25, 2001.

The benefit of U.S. provisional application nos. 60/064,662 filed November 6, 1997, and 60/093,234, filed July 17, 1998 is claimed under 35 U.S.C. 119(e).

The benefit of U.S. application nos. 09/769,864 filed January 25, 2001, and 09/183,412 filed October 30, 1998 is claimed under 35 U.S.C. 120.

An application data sheet is enclosed.

This application contains a Sequence Listing. The computer-readable form in this application is identical with that filed in application no. 09/769,864 filed January 25, 2001. In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in that application as the computer readable form for the instant application. The content of the attached Sequence Listing and of the computer readable form filed in the parent application is the same.

The assignee of the present application is:

Novozymes A/S Krogshoejvej 36 DK-2880 Bagsvaerd Denmark

Applicants request that the assignee information be included in the published patent application.

Direct all correspondence to Customer Number 25908.

Please charge the required fee, estimated to be \$750, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 18, 2003

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600

New York, NY 10110 (212) 840-0097

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## **EXPRESS MAIL CERTIFICATE**

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application for

Alpha-Amylase Mutants Applicants: Borchert et al

Sir:

Express Mail Label No. EV 138339025 US

Date of Deposit: September 18, 2003

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Application Data Sheet
- 4. Preliminary Amendment
- 5. Sequence Listing
- 6. Information Disclosure Statement
- 7. Form PTO/SB/08A
- 8. Executed Declaration

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and to the address indicated above.

Julie Tabarovsky

(Name of person mailing paper(s) or fee)

Signature of person mailing paper(s) or fee)

Mailing Address: Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097